![MSD Profesionales on Twitter: "#Oncología En menos de 24 horas empieza el evento MoveOn y contaremos con el doctor Ricard Mesía @MesiaRicard. #LaOncologíaNosMueve ¿Se lo va a perder? Síganos en RRSS con # MSD Profesionales on Twitter: "#Oncología En menos de 24 horas empieza el evento MoveOn y contaremos con el doctor Ricard Mesía @MesiaRicard. #LaOncologíaNosMueve ¿Se lo va a perder? Síganos en RRSS con #](https://pbs.twimg.com/media/EPjKrXwWoAEE_oS.jpg)
MSD Profesionales on Twitter: "#Oncología En menos de 24 horas empieza el evento MoveOn y contaremos con el doctor Ricard Mesía @MesiaRicard. #LaOncologíaNosMueve ¿Se lo va a perder? Síganos en RRSS con #
![Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology | SpringerLink Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12094-022-02856-1/MediaObjects/12094_2022_2856_Fig1_HTML.png)
Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology | SpringerLink
![Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy](https://www.frontiersin.org/files/Articles/953020/fonc-12-953020-HTML/image_m/fonc-12-953020-t003.jpg)
Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
![Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy](https://www.frontiersin.org/files/MyHome%20Article%20Library/953020/953020_Thumb_400.jpg)
Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcin
![Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy Frontiers | Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy](https://www.frontiersin.org/files/Articles/953020/fonc-12-953020-HTML/image_m/fonc-12-953020-g001.jpg)